|Surprisingly the CEO of WntResearch resigned last Friday. My best guess is that he could not deliver a good enough deal with Big Pharma according to the board and CSO who know the value of Foxy-5. aktietorget.se|
But strange things have happened the last few days. Research raw data (before publication !) for WntResearch's Foxy-5 is available now on this site :
Treatment with the WNT5A-mimicking Peptide Foxy-5 Effectively Reduces the Metastatic Spread of WNT5A-low Prostate Cancer Cells in an Orthotopic Mouse Model
The short and just 2 days old article above regarding the 3D-structure of Foxy-5 and Wnt-5a is written by a long time stockholder (had 99 000 shares as of June 30 2017) and scientist. It supports my own conclusion that Foxy-5 mechanistically via Frizzled-5 most likely captures only the best antimetastatic signaling pathway of Wnt-5a and not the unwanted signaling via the receptors Frizzled-2, Frizzled-7 and ROR2 in breast, colon and prostate cancers.
WntResearch has cancelled their presentation at Nordic Life Science Days Sept 14, and will only participate. So I intepret this that an adequate number of Big Pharma now probably are already serious partner candidates eager to get Foxy-5 :-)
No presentations to the stock market are planned, in spite of the weak balance sheet.
Many clues now point to that a deal regarding Foxy-5 may occur rather soon (I hope) , and could finance Phase II clinical studies with Foxy-5 in breast, colorectal and prostate cancers !
The WNT.ST stock is very volatile now, but once more seem to pull upwards in new optimism :